Question 1

What is Vaborbactam?

Accepted Answer

Vaborbactam is a medication known as a beta-lactamase inhibitor. It is used in combination with the antibiotic meropenem to help prevent certain bacteria from breaking down the antibiotic, allowing the treatment to remain effective against serious infections.

Question 2

What is Vaborbactam used for?

Accepted Answer

Vaborbactam is used to treat complicated urinary tract infections when used in combination therapy (not FDA-approved as monotherapy ).

Question 3

How does Vaborbactam work?

Accepted Answer

Mechanism of Action

Vaborbactam belongs to a class of drugs known as beta-lactamase inhibitors. While it does not kill bacteria on its own, it plays a critical role in treating infections by protecting the antibiotic it is paired with, such as meropenem.

Some bacteria produce specific enzymes called beta-lactamases. These enzymes act like a defense mechanism for the bacteria, breaking down and deactivating antibiotics before they can work. This process is a common cause of antibiotic resistance.

Vaborbactam works by:

Inhibiting enzymes: It binds to and blocks the action of certain beta-lactamase enzymes produced by the bacteria.

Restoring antibiotic activity: By neutralizing these enzymes, vaborbactam prevents the antibiotic from being destroyed.

Enhancing effectiveness: This allows the antibiotic to successfully enter the bacterial cells and kill them.

This medication is specifically designed to target bacteria that have become resistant to other treatments, helping to ensure the accompanying antibiotic remains effective against tough-to-treat infections.

Question 4

What are the active ingredients in Vaborbactam?

Accepted Answer

The active ingredient in Vaborbactam is vaborbactam .

Question 5

What are the side effects of Vaborbactam?

Accepted Answer

Common side effects of Vaborbactam may include:

diarrhea

headache

infusion site reactions

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Vaborbactam?

Accepted Answer

Vaborbactam belongs to the beta-lactamase inhibitor drug class.

Question 7

What is the dosage of Vaborbactam and how do I take it?

Accepted Answer

Administration

Vaborbactam is given as an injection into a vein (intravenous infusion). This medication is administered by a healthcare professional in a medical setting, such as a hospital or clinic. The infusion process usually takes several hours to complete and is typically scheduled at regular intervals throughout the day.

Treatment Duration

The length of treatment depends on the specific type of infection being treated and how well the patient responds to the medication. It is important to complete the full course of treatment as directed by a healthcare provider to ensure the infection is properly managed.

Missed Doses

Because this medication is administered by a healthcare professional, it is unlikely that a dose will be missed. If a scheduled appointment for an infusion is missed, patients should contact their healthcare provider or the medical facility immediately for instructions on rescheduling.

Question 8

Is Vaborbactam safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no well-controlled studies on the use of vaborbactam in pregnant women to inform drug-associated risks. In animal reproduction studies, vaborbactam alone did not cause fetal harm even at high doses. However, vaborbactam is used in combination with meropenem, and animal studies of meropenem have shown some evidence of adverse developmental effects, such as fetal loss.

Pregnant individuals should discuss their medical history and the necessity of the treatment with their doctor to determine if the benefits to the mother outweigh the potential risks to the fetus.

Breastfeeding

It is currently unknown if vaborbactam is excreted in human breast milk. Research indicates that meropenem, which is administered alongside vaborbactam, does pass into breast milk in small quantities. The effects of vaborbactam on a breastfed infant or on milk production are not yet established.

Decisions regarding the use of this medication while breastfeeding should involve a discussion with a healthcare professional, considering the following factors:

The importance of the drug to the mother's health.

The potential risks to the nursing infant from the medication or the mother's underlying condition.

The developmental and health benefits of breastfeeding.

Question 9

What forms and strengths does Vaborbactam come in?

Accepted Answer

Dosage Forms

Vaborbactam is supplied as a sterile, preservative-free powder in single-dose vials. It is only available as a combination product with the antibiotic meropenem.

Administration

This medication is administered by a healthcare professional in a hospital or clinic setting. The process involves the following steps:

Reconstitution: The powder is mixed with a compatible liquid to create a solution.

Dilution: The solution is further diluted into an intravenous (IV) bag.

Infusion: The medicine is delivered slowly into a vein, typically over a period of several hours.

Question 10

What is the FDA approval status of Vaborbactam?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved the combination of meropenem and vaborbactam in August 2017. Vaborbactam is a beta-lactamase inhibitor that is not available as a standalone medication; it is only administered in combination with the carbapenem antibiotic meropenem.

Approved Indications

This combination therapy is indicated for the treatment of patients 18 years of age and older with the following conditions caused by susceptible bacteria:

Complicated urinary tract infections (cUTI)

Pyelonephritis (a type of kidney infection)

The FDA approval was based on clinical trials showing the drug's effectiveness against specific microorganisms, including Escherichia coli , Klebsiella pneumoniae , and Enterobacter cloacae species complex.

Regulatory Status and Safety

The medication is available by prescription only and is administered via intravenous infusion. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with this drug combination. To maintain the effectiveness of the drug and prevent the development of drug-resistant bacteria, the FDA recommends that it be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Question 11

What should I know about Vaborbactam and fda?

Accepted Answer

The U.S. Food and Drug Administration (FDA) approved the combination of meropenem and vaborbactam in August 2017. It is specifically indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI), including a type of kidney infection known as pyelonephritis.

The approval was based on clinical trials demonstrating that the combination was effective against specific susceptible microorganisms. To maintain the effectiveness of the drug and reduce the development of drug-resistant bacteria, the FDA recommends that it only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

During its development, the FDA granted this drug combination several special designations to expedite its availability:

Qualified Infectious Disease Product (QIDP): A status given to antibacterial or antifungal human drugs intended to treat serious or life-threatening infections.

Fast Track: A process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Priority Review: An FDA designation that directs overall attention and resources to the evaluation of applications for drugs that would, if approved, be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions.

Vaborbactam

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Information

FAQ

Found an Error?